Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 14Active not recruiting 14Completed 6Terminated 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

pembrolizumab 111Carboplatin 45Nivolumab 41Paclitaxel 34Cyclophosphamide 32Cisplatin 32Gemcitabine 30atezolizumab 27Specimen Handling 25venetoclax 24Magnetic Resonance Spectroscopy 24Pemetrexed 23fludarabine 22Biopsy 22Radiotherapy 21Ipilimumab 21Docetaxel 21Bevacizumab 21Azacitidine 21Radiosurgery 18durvalumab 17Fluorouracil 17Dexamethasone 17Cetuximab 16fludarabine phosphate 14Trastuzumab 14Leucovorin 13Cytarabine 13tislelizumab 12olaparib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × gallium 68 PSMA-11 × 1 year × Clear all
NCT04716725 2026-05-15

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

University of California, San Francisco

Phase 2 Terminated
15 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT04176497 2025-12-11

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

UNC Lineberger Comprehensive Cancer Center

Phase 2 Terminated
8 enrolled 17 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡